Key Takeaways Docusign's first-quarter billings missed estimates, and it lowered its full-year billings outlook.The ...

The main reason for the downturn in Moderna’s stock is a significant drop in the demand for its COVID-19 vaccine.

Is ENPH stock a worthwhile purchase following such a considerable drop? This steep decrease for Enphase Energy stands out ...

On Friday, RBC Capital analysts maintained their Sector Perform rating and a $90.00 price target for Docusign Inc ... and led to a significant decline in the stock’s after-hours trading.

DocuSign has experienced a notable decline in its stock price, dropping by 15.61% over the past week. This movement comes amidst a series of analyst reports maintaining a ‘Hold ...

which showed mixed results and led to a significant decline in the stock’s after-hours trading. According to InvestingPro data, the stock is currently trading below its Fair Value, despite showing ...

RBC Capital analysts maintained their Sector Perform rating and a $90.00 price target for Docusign Inc. (NASDAQ: DOCU). This decision follows the company’s recent quarterly report, which showed mixed ...

The stock has rebounded over 23% since its March low, and technical signals still favor a retest of $100 if bulls defend current levels. The decline might be less of a structural breakdown and more of ...

Docusign (NASDAQ: DOCU) stock plunged 19.3% through 11:11 a.m. ET this morning despite "beating earnings" on both top and ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer. The Motley Fool reaches millions of people every month through our premium ...

The company lowered its full-year earnings forecast to $14.58 to $14.78 per share, down from prior guidance of $14.95 to ...